HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer.

ABSTRACT:

Background

HAGE protein is a known immunogenic cancer-specific antigen.

Methods

The biological, prognostic and predictive values of HAGE expression was studied using immunohistochemistry in three cohorts of patients with BC (n=2147): early primary (EP-BC; n=1676); primary oestrogen receptor-negative (PER-BC; n=275) treated with adjuvant anthracycline-combination therapies (Adjuvant-ACT); and primary locally advanced disease (PLA-BC) who received neo-adjuvant anthracycline-combination therapies (Neo-adjuvant-ACT; n=196). The relationship between HAGE expression and the tumour-infiltrating lymphocytes (TILs) in matched prechemotherapy and postchemotherapy samples were investigated.

Results

Eight percent of patients with EP-BC exhibited high HAGE expression (HAGE+) and w

SUBMITTER: Abdel-Fatah TM 

PROVIDER: S-EPMC4021517 | biostudies-literature | 2014 May

REPOSITORIES: biostudies-literature